Bijdrage van Herman Pieterse

We are proud to announce we will be present in the upcoming 34th Edition of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), from 27 to 30 of April in Barcelona, Spain. ECCMID is renowned as the premier gathering for professionals in the field of clinical microbiology, attracting a diverse array of researchers, practitioners, and industry leaders from across Europe and beyond. As the world’s leading company in rapid AST with its ultra-rapid 2h AST, we have shown in past editions our technology’s transformational technology. In this edition, we will showcase how this technology is now used in real hospitals, and how it impacts the life of real patients in Europe. We are eager to engage with fellow experts, share insights, and contribute to the ongoing dialogue surrounding microbiology research and innovation. Do not miss the opportunity to visit FASTinov at booth D39, where our growing team will be on hand to showcase our cutting-edge solutions and discuss how they can address the evolving needs of clinical microbiology laboratories. Learn from our team how hospitals in Europe are already using our technology to improve sepsis patient outcomes. Additionally, we invite you to explore our three latest posters, which highlight our groundbreaking R&D efforts, and further confirm FASTinov’s ability to consistently deliver same-shift AST results as seen in the 6 customer evaluations completed last year (some now in routine use served by local partner Quilaban), in Portugal: ·       A simple protocol for rapid bacterial identification by MALDI-TOF MS directly from positive blood cultures (P2005 – 27th April) ·       FASTinov ultrarapid AST directly from positive blood cultures: performance evaluation study in 6 Portuguese hospitals (P1629 – 29th April) ·       Carbapenemase detection by flow cytometry: a rapid and promising technology (P1775 – 29th April) #FASTinov #ultrarapid #AST #ECCMID

FASTinov and Quilaban Showcase Revolutionary Ultra Rapid Antimicrobial Susceptibility Test at the XIII Portuguese National Clinical Pathology Congress in Algarve FASTinov proudly announces its recent participation alongside Quilaban at the XIII edition of the esteemed Portuguese National Clinical Pathology Congress held in Almancil, Algarve. The congress, which convened renowned clinicians, researchers, and industry experts, provided an invaluable platform for FASTinov and Quilaban to showcase their groundbreaking ultra-rapid Antimicrobial Susceptibility Test (2-hour AST), which is poised to revolutionize diagnostic practices in bloodstream infections and sepsis. Having taken place from 7 to 9 March, the Clinical Pathology Congress served as an opportune moment for FASTinov to introduce its cutting-edge technology to an audience deeply invested in advancing diagnostic methodologies. As attendees explored the diverse array of exhibits and presentations, the joint presence of FASTinov and Quilaban at the congress stand underscored their shared commitment to combatting antimicrobial resistance and improving bloodstream infection and sepsis patient care across Portugal and beyond. "Participating in the Clinical Pathology Congress alongside our esteemed distributor allowed us to collectively showcase the transformative potential of our ultra-rapid AST in addressing the critical challenge of antimicrobial resistance," remarked Nuno Afonso, CEO of FASTinov. "We were thrilled to engage with clinicians, pathologists, and industry leaders, demonstrating how our products can enhance diagnostic workflows and optimize treatment strategies." By delivering results in under 2 hours, FASTinov’s products can provide an antibiogram in the same shift when the blood culture flags positive. Engaging discussions, informative presentations, and insightful interactions further highlighted the significance of same-shift results in shaping the future of diagnostic practices. As FASTinov and Quilaban continue to lead the charge in biotechnological innovation, their participation in the Clinical Pathology Congress marks a significant milestone in their collective mission to combat antimicrobial resistance and elevate the standard of patient care. #FASTinov #Quilaban #patologiaclinica #clinicalpathology #AST #SPPC

🎉 Reflecting on a Remarkable Year: FASTinov's Achievements in 2023 and Exciting Plans for 2024! 🚀  As we close the chapter on 2023, we at FASTinov are incredibly proud of the milestones we've achieved and the impact we've made in revolutionizing sepsis management and blood stream infection control. In 2023, our innovative FASTinov® technology received exceptional feedback from prestigious hospitals, showcasing its ability to deliver ultra-rapid antimicrobial susceptibility testing (AST) results within just 2 hours. The successful completion of customer evaluations at leading institutions, including Instituto Português de Oncologia, Porto, Hospital Santo António, Porto, marked a pivotal moment in our journey. Additionally, we were thrilled to secure pre-Series A financing of 3.5 million euros from private investors, further validating the potential of our technology. This funding will fuel our continued growth and expansion efforts as we strive to bring our solutions to healthcare providers globally. Looking ahead to 2024, we are excited to build upon our momentum and expand our reach even further. Our team has been actively engaged at various scientific conferences, including participations at the 29th Infection and Sepsis Symposium organized by GIS in Porto, the 14th International Congress on Prevention and Control of Infection and Antimicrobial Resistance organized by The Luz Saúde Group in Lisbon, and upcoming engagements at the XIII Portuguese National Congress of Clinical Pathology organized by SPPC in Almancil, Portugal, the 51st national congress of the Associazione Microbiologi Clinici Italiani (AMCLI 2024) in Rimini, Italy, and SEIMC 2024, Zaragoza, Spain, among others. You can follow up our latest news at https://lnkd.in/dmN2YJtP We are committed to leading the charge in sepsis management and blood stream infection control, with our 2-hour AST solution providing same-shift results for 100% of samples analysed. We eagerly anticipate the opportunity to engage with current and new partners alike, as we work together to drive positive change in healthcare. Thank you to our dedicated team, supportive partners, and valued customers for your continued trust and collaboration. Here's to a successful 2023 and an even brighter future ahead in 2024! #FASTINOV #Innovation #SepsisManagement #AntimicrobialResistance #Healthcare #AST #FutureofHealthcare #Teamwork #Partnerships